RT Journal Article
SR Electronic
T1 The power and limitations of genomics to track COVID-19 outbreaks: a case study from New Zealand
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.28.20221853
DO 10.1101/2020.10.28.20221853
A1 Jemma L Geoghegan
A1 Jordan Douglas
A1 Xiaoyun Ren
A1 Matthew Storey
A1 James Hadfield
A1 Olin K Silander
A1 Nikki E Freed
A1 Lauren Jelley
A1 Sarah Jefferies
A1 Jillian Sherwood
A1 Shevaun Paine
A1 Sue Huang
A1 Andrew Sporle
A1 Michael G Baker
A1 David R Murdoch
A1 Alexei J Drummond
A1 David Welch
A1 Colin R Simpson
A1 Nigel French
A1 Edward C Holmes
A1 Joep de Ligt
YR 2020
UL http://medrxiv.org/content/early/2020/11/03/2020.10.28.20221853.abstract
AB Background Real-time genomic sequencing has played a major role in tracking the global spread and local transmission of SARS-CoV-2, contributing greatly to disease mitigation strategies. After effectively eliminating the virus, New Zealand experienced a second outbreak of SARS-CoV-2 in August 2020. During this August outbreak, New Zealand utilised genomic sequencing in a primary role to support its track and trace efforts for the first time, leading to a second successful elimination of the virus.Methods We generated the genomes of 80% of the laboratory-confirmed samples of SARS-CoV-2 from New Zealand’s August 2020 outbreak and compared these genomes to the available global genomic data.Findings Genomic sequencing was able to rapidly identify that the new COVID-19 cases in New Zealand belonged to a single cluster and hence resulted from a single introduction. However, successful identification of the origin of this outbreak was impeded by substantial biases and gaps in global sequencing data.Interpretation Access to a broader and more heterogenous sample of global genomic data would strengthen efforts to locate the source of any new outbreaks.Funding This work was funded by the Ministry of Health of New Zealand, New Zealand Ministry of Business, Innovation and Employment COVID-19 Innovation Acceleration Fund (CIAF-0470), ESR Strategic Innovation Fund and the New Zealand Health Research Council (20/1018 and 20/1041).Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by the Ministry of Health of New Zealand, New Zealand Ministry of Business, Innovation and Employment COVID-19 Innovation Acceleration Fund (CIAF-0470), ESR Strategic Innovation Fund and the New Zealand Health Research Council (20/1018 and 20/1041).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is available on GISAID database https://www.gisaid.org/